PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) plus BEVACIZUMAB (BEV) IN BEV-NAIVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

被引：0
|
作者：
Reardon, David [1 ]
Kaley, Thomas [2 ]
Dietrich, Jorg [3 ]
Clarke, Jennifer [4 ]
Dunn, Gavin [5 ]
Lim, Michael [6 ]
Cloughesy, Tim [7 ]
Gan, Hui [8 ]
Park, Andrew [9 ]
Schwarzenberger, Paul [9 ]
Ricciardi, Toni [9 ]
Macri, Mary [9 ]
Ryan, Aileen [9 ]
Venhaus, Ralph [9 ]
机构：
[1] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Washington Univ, St Louis, MO USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[7] Univ Calif Los Angeles, Neurooncol, Los Angeles, CA USA
[8] Austin Hosp, Melbourne, ACT, Australia
[9] Ludwig Inst Canc Res, New York, NY USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ATIM-38
引用
收藏
页码：10 / 10
页数：1
相关论文
共 50 条
  • [41] A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus-associated head and neck squamous cell cancer.
    Aggarwal, Charu
    Halmos, Balazs
    Porosnicu, Mercedes
    Saba, Nabil F.
    Sukari, Ammar
    Grethlein, Sara Jo
    Mehra, Ranee
    Adkins, Douglas
    Fidler, Mary J.
    Kumar, Rakesh
    Yang, Jie
    Abdullah, Shaad Essa
    Haigentz, Missak
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC).
    Brufsky, Adam M.
    Hurvitz, Sara A.
    Perez, Edith A.
    Yamamoto, Hideharu
    Valero, Vicente
    O'Neill, Vincent
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [43] A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
    Lassen, Ulrik Niels
    Mau-Soerensen, Morten
    Kung, Andrew L.
    Wen, Patrick Y.
    Lee, Eudocia Quant
    Plotkin, Scott R.
    Muhic, Aida
    Rashal, Tami
    Williams, Tony
    McCauley, Dilara
    Ellis, Joel
    Saint-Martin, Jean-Richard
    Carlson, Robert
    Frenkel, Ran
    Shacham, Sharon
    Mirza, Mansoor Raza
    Kauffman, Michael
    Lassman, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
    Mau-Sorensen, Morten
    Plotkin, Scott Randall
    Wen, Patrick Y.
    Kung, Andrew L.
    Lassen, Ulrik Niels
    Saint-Martin, Jean-Richard
    Wright, Greg
    Chudnovsky, Aleksander
    Ellis, Joel
    Friedlander, Sharon
    van Eijk, Bert
    Shacham, Sharon
    Kauffman, Michael G.
    Lassman, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288)
    Hinchcliff, Emily
    Gardiner, Elisabeth
    Westin, Shannon
    Bayer, Virginia
    Rangel, Kelly
    Lito, Kathryn
    Fellman, Bryan
    Yuan, Ying
    Sood, Anil
    Lu, Karen
    Jazaeri, Amir
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S166 - S167
  • [46] Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial
    Tournigand, Christophe
    Samson, Benoit
    Scheithauer, Werner
    Lledo, Gerard
    Viret, Frederic
    Andre, Thierry
    Ramee, Jean Francois
    Tubiana-Mathieu, Nicole
    Dauba, Jerome
    Dupuis, Olivier
    Rinaldi, Yves
    Mabro, May
    Aucoin, Nathalie
    Khalil, Ahmed
    Latreille, Jean
    Louvet, Christophe
    Brusquant, David
    Bonnetain, Franck
    Chibaudel, Benoist
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb) in patients with recurrent glioblastoma (GBM).
    Cher, Lawrence
    Nowak, Anna K.
    Iatropoulos, George
    Lee, Weon Sup
    Lee, Seon Young
    Shim, Sang Ryeol
    Yoo, Jin San
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] EFFICACY AND SAFETY OF TREATMENT WITH BEVACIZUMAB (BEV) plus CHEMOTHERAPY (CT) BEYOND FIRST PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) PREVIOUSLY TREATED WITH BEV plus CT: AGE SUBGROUP ANALYSIS FROM A RANDOMISED PHASE III INTERGROUP STUDY (ML18147)
    Bouche, O.
    Steffens, C.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Osterlund, P.
    von Moos, R.
    Reyes-Rivera, I.
    Sersch, M. A.
    Arnold, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 190 - 191
  • [49] A Phase II, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone in Japanese Patients With Recurrent Malignant Glioma
    Matsutani, M.
    Nishikawa, R.
    Kobayashi, H.
    Takano, S.
    Shinoura, N.
    Nagane, M.
    Narita, Y.
    Aokis, T.
    Sugiyama, K.
    Kuratsu, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S575 - S575
  • [50] PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Weathers, Shiao-Pei
    Kamiya-Matsuoka, Carlos
    Harrison, Rebecca
    Liu, Diane
    Sanqui, Edmund
    Dervin, Shannon
    Yun, Cindy
    Loghin, Monica
    Penas-Prado, Marta
    Majd, Nazanin
    Yung, W. K. Alfred
    O'Brien, Barbara
    de Groot, John
    NEURO-ONCOLOGY, 2020, 22 : 35 - 35
12345